Higher FASN expression was observed to be linked to higher pathological stages and poorer patient prognosis in breast [88,89,90], ovarian [50,91], cervical [52,53] and endometrial [92,93,94,95] cancers (Table 1). This evidence concerns the gene FASN and cancer.